Merck KGaA and GSK's Bintrafusp Alfa Fails to Meet its Co-Primary Endpoints in Lung Cancer Study
Shots:
- Merck KgaA provides an update on its P-III INTR@PID Lung 037 study and the extensive INTR@PID clinical trial program assessing bintrafusp alfa for patients with BTC and cervical cancer
- Based on the IDMC’s recommendation- Merck will discontinue the INTR@PID Lung 037 study as it fails to meet its co-1EPs- specifically PFS. The ongoing clinical trial INTR@PID Lung 037 includes 1L treatment of patients with stage IV NSCLS having PD-L1 expression
- The company will further evaluate bintrafusp alfa in other studies. GSK has high hopes with the drug as it has paid $4.2B+ in the collaboration signed in 2019
Ref: Merck KgaA | Image: Merck KgaA
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com